EUVIMEDEUVIMED entdecken
EditorialKommentarKohortenstudie

Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study

Simone Cazzaniga iD, Luigi Naldi iD, Luca Borradori iD

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad005 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Simone Cazzaniga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Pemphigus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusHumansRituximabCohort StudiesAzathioprineMycophenolic AcidTreatment Outcome

Substanzen

RituximabAzathioprineMycophenolic Acid

Autor:innen und Institutionen

  • Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
  • Centro Studi GISED, Bergamo, Italy.
  • Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.

ORCID-Profile: Simone Cazzaniga, Luigi Naldi, Luca Borradori

Zitieren

APA

Cazzaniga, S., Naldi, L., & Borradori, L. (2023). Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad005

Vancouver

Cazzaniga S, Naldi L, Borradori L. Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad005

BibTeX
@article{Cazzaniga2023,
  author = {Cazzaniga, Simone and Naldi, Luigi and Borradori, Luca},
  title = {Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad005}
}
Kostenlos starten →